PDG70 OPIOID USE IN CHRONIC NON-CANCER PAIN: ANALYSIS USING MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATABASE

We jointly model amount of expenditure for outpatient visits and number of outpatient visits by considering both dependence and simultaneity by proposing a bivariate structural model that describes both variables, specified in terms of their conditional distributions. For that reason, we assume that the conditional expectation of expenditure for outpatient visits with respect to the number of outpatient visits and also, the number of outpatient visits expectation with respect to the expenditure for outpatient visits is related by taking a linear relationship for these conditional expectations. Furthermore, one of the conditional distributions obtained in our study is used to derive Bayesian premiums which take into account both the number of claims and the size of the correspondent claims. Our proposal is illustrated with a numerical example based on data of health care use taken from Medical Expenditure Panel Survey (MEPS), conducted by the U.S. Agency of Health Research and Quality.

Download Full-text

Patient characteristics associated with multiple pharmacy use in the U.S. population: Findings from the Medical Expenditure Panel Survey

Research in Social and Administrative Pharmacy ◽

10.1016/j.sapharm.2014.10.004 ◽

2015 ◽

Vol 11 (4) ◽

pp. 507-516 ◽

Cited By ~ 4

Author(s):

Kevin A. Look

Keyword(s):

Medical Expenditure Panel Survey ◽

Patient Characteristics ◽

Medical Expenditure ◽

Panel Survey ◽

The U.S

Download Full-text

Trends of medical expenditures and quality of life in US adults with diabetes: the medical expenditure panel survey, 2002–2011

Health and Quality of Life Outcomes ◽

10.1186/s12955-017-0651-7 ◽

2017 ◽

Vol 15 (1) ◽

Cited By ~ 12

Author(s):

Jennifer A. Campbell ◽

Kinfe G. Bishu ◽

Rebekah J. Walker ◽

Leonard E. Egede

Keyword(s):

Quality Of Life ◽

Medical Expenditure Panel Survey ◽

Medical Expenditures ◽

Medical Expenditure ◽

Panel Survey

Download Full-text

Are There Racial Disparities in Psychotropic Drug Use and Expenditures in a Nationally Representative Sample of Men in the United States? Evidence From the Medical Expenditure Panel Survey

American Journal of Men s Health ◽

10.1177/1557988313496564 ◽

2013 ◽

Vol 8 (1) ◽

pp. 82-90 ◽

Cited By ~ 6

Author(s):

Geraldine Pierre ◽

Roland J. Thorpe ◽

Gniesha Y. Dinwiddie ◽

Darrell J. Gaskin

Keyword(s):

United States ◽

Drug Use ◽

Racial Disparities ◽

Psychotropic Drug ◽

Medical Expenditure Panel Survey ◽

The United States ◽

Medical Expenditure ◽

Panel Survey ◽

Psychotropic Drug Use ◽

Nationally Representative

This article sought to determine whether racial disparities exist in psychotropic drug use and expenditures in a nationally representative sample of men in the United States. Data were extracted from the 2000-2009 Medical Expenditure Panel Survey, a longitudinal survey that covers the U.S. civilian noninstitutionalized population. Full-Year Consolidated, Medical Conditions, and Prescribed Medicines data files were merged across 10 years of data. The sample of interest was limited to adult males aged 18 to 64 years, who reported their race as White, Black, Hispanic, or Asian. This study employed a pooled cross-sectional design and a two-part probit generalized linear model for analyses. Minority men reported a lower probability of psychotropic drug use (Black = −4.3%, 95% confidence interval [CI] = [−5.5, −3.0]; Hispanic = −3.8%, 95% CI = [−5.1, −2.6]; Asian = −4.5%, 95% CI = [−6.2, −2.7]) compared with White men. After controlling for demographic, socioeconomic, and health status variables, there were no statistically significant race differences in drug expenditures. Consistent with previous literature, racial and ethnic disparities in the use of psychotropic drugs present problems of access to mental health care and services.

Download Full-text